Aspirin thins blood by inhibiting platelet aggregation
the verdict
SUPPORTED
the evidence backs this
confidence 81/100
Aspirin acts as an antiplatelet agent by inhibiting cyclooxygenase and reducing thromboxane-dependent platelet activation, thereby preventing platelet aggregation.
Evidence for · 5
Does the timing of aspirin administration influence its antiplatelet effect – review of literature on chronotherapy
2018 · cited by 7
Paper [0] discusses aspirin's mechanism of action involving the inhibition of cyclooxygenase and thromboxane A2, giving rise to its antiplatelet effect.
See more details
More for · 4
Enhanced Antiplatelet Effects of Clopidogrel plus Acetylsalicylic Acid Compared with Acetylsalicylic Acid Alone or Combined with Extended-Release Dipyridamole in Healthy Volunteers
2005 · cited by 4
Paper [1] evaluates acetylsalicylic acid (ASA) as an antiplatelet agent capable of inhibiting arachidonic acid-induced platelet aggregation.
Synthesis, Characterization, and Application of 2-((3-(Chloromethyl)-benzoyl)oxy)benzoic Acid: A Review
2022 · cited by 3
Paper [2] notes that aspirin is widely used due to its additional advantages in preventing platelet aggregation.
Delayed Rewarming Thrombocytopenia (DRT): A Temperature-Dependent Platelet Aggregation Disorder.
2026 · cited by 0
Paper [6] states that aspirin blocks the second phase of platelet aggregation.
The crucial role of thromboxane A<sub>2</sub> in colorectal cancer development and metastasis: a key target for anticancer therapy.
2026 · cited by 0
Paper [11] explains that low-dose aspirin irreversibly and selectively inhibits COX-1 activity in platelets, reducing thromboxane-dependent platelet activation.